Systematic review finds GLP-1 drugs improve diverse dermatologic conditions (psoriasis, HS, HAIR-AN syndrome, Hailey-Hailey disease, acne keloidalis, folliculitis decalvans, alopecia, scleroderma) through immunologic, metabolic, and barrier-modulating mechanisms.
8+ skin diseases improvedGLP-1 drugs improve diverse dermatologic conditions from psoriasis to alopecia—expanding their therapeutic scope into dermatology
What the researchers found
Improved conditions: psoriasis, HS, HAIR-AN syndrome, Hailey-Hailey, acne keloidalis, folliculitis decalvans, androgenic alopecia, localized scleroderma. Mechanisms: immunologic, metabolic, barrier-modulating. Evidence: controlled trials to case reports.
Why it matters
Many skin diseases lack effective treatments. Discovering that GLP-1 drugs—already taken by millions—improve diverse skin conditions opens new treatment avenues for dermatologists.
How the study worked
Systematic review of literature linking GLP-1RA use to improvement of preexisting dermatologic conditions.
What this study cannot tell us
Systematic review with varying evidence quality. Most evidence from small studies or case reports. Cannot determine optimal dosing for skin conditions. May reflect publication bias.
How to read the evidence
Systematic review with heterogeneous evidence quality. Hypothesis-generating for dermatologic applications.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs' anti-inflammatory effects extend to the skin—one of the largest immune organs. This adds dermatology to the growing list of medical specialties that may benefit from GLP-1 therapy.
Questions still open
- Should dermatologists prescribe GLP-1 drugs for skin diseases?
- Is the skin benefit from weight loss, anti-inflammation, or both?
- Which skin conditions would benefit most from dedicated GLP-1 trials?
Common questions
Can GLP-1 drugs help skin problems?
Should I tell my dermatologist I am on a GLP-1 drug?
Read the original research
Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review.
Cureus, 17(9), e93282
Citation
Tassavor, Bryan; Al Salem, Sultan. (2025). Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review.. Cureus, 17(9), e93282. https://doi.org/10.7759/cureus.93282